ArticleBMC nephrology2026
Stage-dependent alterations in MaR1 in pediatric chronic kidney disease: a potential candidate biomarker.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic kidney disease (CKD) in children is characterized by persistent inflammation and oxidative stress, contributing to progressive loss of renal function and multisystem involvement. Maresin 1 (MaR1), a specialized pro-resolving lipid mediator derived from docosahexaenoic acid (DHA), plays a role in the resolution of inflammation and tissue repair. However, its circulating concentrations in pediatric CKD have not been examined. This study aimed to determine serum MaR1 levels across CKD stages in children and to assess its potential relevance as a biomarker reflecting disease severity.
methodsChildren were categorized as healthy controls or assigned to CKD stages 1-5 according to estimated glomerular filtration rate (eGFR). In patients receiving hemodialysis, blood samples were obtained 48 h after the preceding dialysis session and immediately before the subsequent session. Serum MaR1 concentrations were measured by enzyme-linked immunosorbent assay (ELISA). Group comparisons were performed using one-way ANOVA with Tukey's post-hoc test (p < 0.05).
resultsSerum MaR1 levels differed significantly among the six groups (p < 0.001). Mean MaR1 concentrations were 110.20 ± 18.15 pg/mL in healthy controls, 20.01 ± 7.23 pg/mL in CKD stage 1, 39.61 ± 7.60 pg/mL in stage 2, 60.73 ± 12.79 pg/mL in stage 3, 203.86 ± 22.06 pg/mL in stage 4, and 284.56 ± 25.75 pg/mL in stage 5. MaR1 levels showed a marked reduction at stage 1, followed by progressive recovery and substantial elevation in advanced CKD.
conclusionsSerum MaR1 concentrations show a stage-dependent pattern in pediatric CKD, characterized by marked suppression at stage 1 followed by progressive recovery and elevation in advanced stages. These findings suggest that circulating MaR1 may represent a candidate biomarker of disease-related inflammatory dynamics; however, its clinical utility requires validation in larger longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.